Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Rebinyn

- PMLiVE

Novo Nordisk will work with IBM on diabetes care

Development of digital platform to help diabetics and their doctors manage their illness

- PMLiVE

Novo Nordisk says Victoza outperforms SGLT2 inhibitors

Comparesthe GLP-1 agonist to Invokana, Jardiance and Farxiga

- PMLiVE

PMEA 2015 win for Novo’s Changing Diabetes in Children

Company wins the EY Award for SociallyResponsible Initiatives

Biogen Idec building

Biogen and Sobi’s Elocta wins EU approval

First haemophilia A treatment to offer prolonged protection against bleeding

- PMLiVE

BPL bags FDA approval for rare bleeding disorder therapy

First drug approved for hereditary Factor X deficiency

- PMLiVE

Novo Nordisk finally bags insulin degludec approval in US

Aims to get Tresiba and Ryzodeg back on course 

Novo launches online news channel for haemophilia patients

New medical information website aims to be a 'simple, centralised repository'

- PMLiVE

Genzyme opts into gene silencing therapy for haemophilia

Interim results show positive benefits for ALN-AT3

- PMLiVE

Novo Nordisk appoints new senior principal clinical scientist

Stephen Gough joins the Danish diabetes giant

- PMLiVE

New data arms Novo Nordisk for insulin battle with Sanofi

Tresibaand Xultophy boosted by studies presented at EASD 

- PMLiVE

Novo collaborates with MIT on next-gen drug delivery devices

Aims to create new delivery vehicles for administration of peptides

- PMLiVE

Novo Nordisk acquires two US biopharma companies

Strikes deals with Calibrium LLC and MB2

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links